Ratings by Barclays (Eliana Merle)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/22/2026 | uniQure BV | QURE | Upgrade | Overweight (Equalweight) |
46.29 (44.39) |
-4.1% | Details | |
| 6/18/2026 | uniQure BV | QURE | Upgrade | Overweight (Equalweight) |
48.16 (44.39) |
-7.83% | Details | |
| 6/17/2026 | uniQure BV | QURE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/19/2026 | Gossamer Bio Inc. | GOSS | Maintain | Underweight (N/A) |
|
Details | ||
| 5/15/2026 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2026 | MBX Biosciences Inc | MBX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2026 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2026 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/1/2026 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2026 | Apellis Pharmaceuticals | APLS | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/25/2026 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/25/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/23/2026 | uniQure BV | QURE | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/10/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2026 | Regeneron Pharma | REGN | New Coverage | Overweight (N/A) |
787.50 (612.50) |
-22.22% | Details | |
| 3/3/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2026 | Gossamer Bio Inc. | GOSS | Downgrade | Underweight (Overweight) |
2.13 (0.16) |
-92.49% | Details | |
| 2/23/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2026 | Tyra Biosciences | TYRA | New Coverage | Overweight (N/A) |
30.17 (30.14) |
-0.1% | Details | |
| 1/28/2026 | MBX Biosciences Inc | MBX | New Coverage | Overweight (N/A) |
36.60 (43.91) |
19.97% | Details | |
| 1/28/2026 | Regenxbio Inc. | RGNX | New Coverage | Overweight (N/A) |
13.85 (9.07) |
-34.51% | Details | |
| 1/28/2026 | uniQure BV | QURE | New Coverage | Equalweight (N/A) |
25.27 (48.16) |
90.58% | Details | |
| 1/28/2026 | Sarepta Therapeutics | SRPT | New Coverage | Equalweight (N/A) |
22.80 (17.65) |
-22.59% | Details | |
| 1/28/2026 | Moderna | MRNA | New Coverage | Equalweight (N/A) |
47.99 (59.35) |
23.67% | Details | |
| 1/28/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Equalweight (N/A) |
6.03 (7.10) |
17.74% | Details | |
| 1/28/2026 | Kymera Therapeutics | KYMR | New Coverage | Overweight (N/A) |
71.06 (99.45) |
39.95% | Details | |
| 1/28/2026 | BridgeBio Pharma | BBIO | New Coverage | Overweight (N/A) |
77.81 (68.92) |
-11.43% | Details | |
| 1/28/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Overweight (N/A) |
81.00 (75.89) |
-6.31% | Details | |
| 1/28/2026 | Apellis Pharmaceuticals | APLS | New Coverage | Equalweight (N/A) |
21.99 (41.03) |
86.58% | Details | |
| 1/28/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
56.78 (55.90) |
-1.55% | Details | |
| 1/28/2026 | 4D Molecular Therapeutics | FDMT | New Coverage | Overweight (N/A) |
7.97 (10.42) |
30.74% | Details | |
| 1/28/2026 | Gossamer Bio Inc. | GOSS | New Coverage | Overweight (N/A) |
2.66 (2.13) |
-19.92% | Details | |
| 1/28/2026 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
233.65 (228.00) |
-2.42% | Details | |
| 1/28/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Overweight (N/A) |
361.35 (286.41) |
-20.74% | Details | |
| 1/28/2026 | Inventiva SA | IVA | New Coverage | Overweight (N/A) |
7.07 (3.51) |
-50.35% | Details | |
| 1/28/2026 | Insmed | INSM | New Coverage | Overweight (N/A) |
159.72 (98.61) |
-38.26% | Details | |
| 1/28/2026 | Madrigal Pharmaceuticals | MDGL | New Coverage | Overweight (N/A) |
499.17 (512.88) |
2.75% | Details | |
| 1/28/2026 | Altimmune | ALT | New Coverage | Overweight (N/A) |
5.66 (2.93) |
-48.23% | Details | |
| 1/28/2026 | PTC Therapeutics | PTCT | New Coverage | Overweight (N/A) |
76.23 (80.96) |
6.2% | Details | |
| 1/28/2026 | Vertex | VRTX | New Coverage | Overweight (N/A) |
476.84 (466.79) |
-2.11% | Details |
